Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Year of publication: |
2007
|
---|---|
Authors: | Raftery, J. ; Clegg, A. ; Jones, J. ; Tan, S.C. ; Lotery, A. |
Subject: | RE Ophthalmology | R Medicine |
-
Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales
(2004)
-
Mathematical modelling of infectious diseases
Keeling, Matthew James, (2009)
-
The impact of dropouts on the analysis of dose-finding studies with recurrent event data
Akacha, Mouna, (2010)
- More ...
-
A review of health care models for coronary heart disease interventions
Cooper, K., (2007)
-
Roderick, P., (2003)
-
Cooper, K., (2008)
- More ...